^
    CANCER:

    Gastroesophageal Junction Adenocarcinoma





    Show legend
    Group by Gene:
    nivolumab
    pembrolizumab
    sintilimab
    		0
    PD1 inhibitor
    tislelizumab
    camrelizumab
    pucotenlimab
    dostarlimab-gxly
    1
    DNA synthesis inhibitor, Thymidylate synthase inhibitor
    cisplatin + capecitabine
    2
    Thymidylate synthase inhibitor
    5-fluorouracil
    capecitabine
    3
    VEGFR-2 inhibitor
    ramucirumab
    rivoceranib
    HER2 inhibitor
    trastuzumab
    trastuzumab-dkst
    trastuzumab-dttb
    		4
    HER2 inhibitor
    trastuzumab-anns
    trastuzumab-qyyp
    trastuzumab-pkrb
    Zercepac (trastuzumab biosimilar)
    KN026
    Her-VAXX
    5
    Thymidine phosphorylase inhibitor
    trifluridine / tipiracil
    6
    Topoisomerase I inhibitor
    irinotecan
    zolbetuximab
    		7
    CLDN18.2 inhibitor
    TST001
    AB011
    8
    DNA synthesis inhibitor, DNA cross linking agent, Thymidylate synthase inhibitor
    5-fluorouracil + oxaliplatin
    capecitabine + oxaliplatin
    9
    DNA synthesis inhibitor, DNA cross linking agent
    oxaliplatin
    10
    Thymidylate synthase inhibitor, Topoisomerase I inhibitor
    5-fluorouracil + irinotecan
    11
    FGFR2b inhibitor
    AMG 552
    PD-L1 inhibitor
    atezolizumab
    		12
    PD-L1 inhibitor
    sugemalimab
    durvalumab
    avelumab
    13
    PD1 inhibitor, CTLA4 inhibitor
    nivolumab + ipilimumab
    cadonilimab
    14
    DKK1 protein inhibitor
    DKN-01
    15
    TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor
    larotrectinib
    16
    VEGFR-2 inhibitor, HER2 inhibitor
    trastuzumab + ramucirumab
    17
    CLDN18.2-targeted CAR-T immunotherapy
    CT041
    IBI-345
    pembrolizumab + trastuzumab
    pembrolizumab + margetuximab
    		18
    HER2 inhibitor, PD1 inhibitor
    tislelizumab + ZW25
    trastuzumab + camrelizumab
    trastuzumab + tislelizumab
    19
    DKK1 protein inhibitor, PD1 inhibitor
    tislelizumab + DKN-01
    pembrolizumab + DKN-01
    20
    HER2 inhibitor, HER2 dimerization inhibitor
    trastuzumab + pertuzumab
    21
    MEK inhibitor, BRAF inhibitor
    trametinib + dabrafenib
    22
    RET inhibitor
    selpercatinib
    23
    VEGFR-2 inhibitor, PD1 inhibitor
    camrelizumab + rivoceranib
    pembrolizumab + ramucirumab
    24
    FGFR inhibitor
    infigratinib
    25
    Tubulin polymerization promoter
    carboplatin
    26
    VEGFR-2 inhibitor, HER2 inhibitor, CD47 inhibitor
    trastuzumab + ramucirumab + ALX148
    27
    HER2 inhibitor, HER3 inhibitor
    MCLA-128
    28
    PD-L1 inhibitor, Multi-tyrosine kinase inhibitor
    durvalumab + cabozantinib tablet
    anlotinib + APL-502
    29
    VEGFR inhibitor, FGFR1 inhibitor, PD1 inhibitor
    toripalimab-tpzi + surufatinib
    30
    PD1 inhibitor, LAG-3 inhibitor
    sintilimab + IBI110
    31
    PD1 inhibitor, Multi-tyrosine kinase inhibitor
    nivolumab + regorafenib
    32
    PD1 inhibitor, CTLA4 inhibitor, CD47 inhibitor
    cadonilimab + AK117
    33
    ATR inhibitor
    M6620
    34
    HER2 inhibitor, γδ TCR modulator
    Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T
    35
    NK cell stimulant
    CYNK-101
    FLOT
    IP
    DP
    FP
    CAPOX
    		36
    Chemotherapy
    CaT
    DOF
    TCF
    FOLFOX
    FOLFIRI
    TPF
    37
    Immunotherapy
    Immunotherapy
    38
    Tubulin polymerization promoter, Bcl2 inhibitor
    paclitaxel
    disitamab vedotin
    		39
    HER2-targeted antibody-drug conjugate, Microtubule inhibitor
    JNJ-0683
    ado-trastuzumab emtansine
    40
    Tubulin polymerization promoter, Bcl2 inhibitor, Thymidylate synthase inhibitor
    paclitaxel + capecitabine
    paclitaxel + 5-fluorouracil
    41
    Microtubule stabilizer, Tubulin polymerization promoter, Thymidylate synthase inhibitor
    carboplatin + docetaxel + 5-fluorouracil
    42
    Microtubule stabilizer, Tubulin polymerization promoter
    docetaxel
    43
    Microtubule stabilizer, Tubulin polymerization promoter, DNA synthesis inhibitor, Thymidylate synthase inhibitor
    cisplatin + docetaxel + 5-fluorouracil
    44
    Microtubule stabilizer, Tubulin polymerization promoter, Topoisomerase I inhibitor
    docetaxel + irinotecan
    45
    PD-L1 inhibitor, CTLA4 inhibitor
    durvalumab + tremelimumab
    46
    HER2-targeted antibody-drug conjugate, Topoisomerase I inhibitor
    fam-trastuzumab deruxtecan-nxki
    SHR-A1811
    47
    CLDN18.2-targeted antibody-drug conjugate, Microtubule inhibitor
    AZD0901
    48
    TrkB receptor inhibitor, TrkC kinase inhibitor, ROS1 inhibitor, TrkA receptor inhibitor, ALK inhibitor, JAK2 inhibitor, TNK2 inhibitor
    entrectinib
    49
    CD137 agonist, HER2 inhibitor
    PRS-343
    50
    VEGFR-2 inhibitor, Caprin-1 inhibitor
    ramucirumab + TRK-950
    51
    PD-L1 inhibitor, HER2 inhibitor, CTLA4 inhibitor
    KN046 + KN026
    52
    PD-L1 inhibitor, VEGF-A inhibitor, TGF-β R2 kinase inhibitor
    bevacizumab + SHR-1701
    53
    TIGIT inhibitor, PD1 inhibitor
    zimberelimab + AB154
    54
    HER2 inhibitor, HER4 inhibitor, PD1 inhibitor, EGFR inhibitor
    camrelizumab + pyrotinib
    55
    Protein synthesis inhibitor, HER2 inhibitor
    MT-5111
    56
    c-MET inhibitor
    AMG 102
    No biomarker
    HER-2 negative
    HER-2 positive
    HER-2 amplification
    HER-2 overexpression
    HER-2 expression
    HER-2 underexpression
    HER-2 positive + HER-2 amplification
    HER-2 mutation
    HER-2 expression + HER-2 amplification
    HER-2 expression + HER-2 D769H
    HER-2 expression + HER-2 L869R
    MSI-H/dMMR
    PD-L1 expression
    PD-L1 overexpression
    HER-2 negative + PD-L1 expression
    CLDN18.2 expression + HER-2 negative
    CLDN18.2 positive + HER-2 negative
    CLDN18.2 positive
    CLDN18.2 overexpression
    CLDN18.2 expression
    HER-2 positive + PD-L1 expression
    PD-L1 expression + HER-2 overexpression
    HER-2 amplification + PD-L1 expression
    DKK1 overexpression
    FGFR2b expression
    FGFR2b overexpression
    FGFR2 amplification
    FGFR2b positive
    FGFR2b overexpression + HER-2 negative
    NTRK3 fusion
    ATR mutation
    MSI-H/dMMR + MLH1 negative + PMS2 negative
    CAPRIN-1 expression
    TP53 mutation
    HER-2 expression + TMB-H
    TMB-H
    PD-1 expression
    NTRK1 fusion
    NTRK2 fusion
    RET fusion
    BRAF V600E
    ATM mutation
    ATRX mutation
    IFNG 6-gene signature
    MET expression
    MET amplification
    HER-2 overexpression + PTEN deletion